Human rhinoviruses (HRVs) are the most frequent cause of acute respiratory illness worldwide. Although HRVs are most commonly associated with mild upperrespiratory- tract disease \[[@R1]\], infection of lower airways does occur \[[@R4]\]. Lower-respiratory-tract infections (LRTIs) related to HRV are increasingly being reported in infants, elderly persons, and immunocompromised patients \[[@R8]\]. HRVs are also implicated in exacerbations of asthma \[[@R9], [@R10]\], chronic bronchitis \[[@R11]\], and acute bronchiolitis \[[@R12]\].

Taxonomically, HRVs are currently grouped into 2 species, human rhinovirus A (HRV-A) and human rhinovirus B (HRV-B), in the genus *Rhinovirus* of the family *Picornaviridae* (\[[@R13], [@R14]\]). These nonenveloped, positive-sense, single-stranded RNA viruses have been classified serologically \[[@R15], [@R16]\] and on the basis of their antiviral susceptibility profiles \[[@R17], [@R18]\], their nucleotidesequence relatedness \[[@R19], [@R20]\], and their use of receptors (intercellular adhesion molecule 1, low-density lipoprotein receptor, and decay-accelerating factor) \[[@R21]\]. Phylogenetic analyses of the VP4/VP2 and VP1 coding regions have indicated the presence of 76 serotypes in genetic group A and 25 serotypes genetic group B \[[@R18], [@R24]\].

An agent is commonly not implicated in up to 50% of cases of severe respiratory disease, despite the application of polymerase-chain-reaction (PCR) assays as well as classical diagnostic methods, including antigen tests, serology, and culture methods. Broad-range molecular assay systems, such as multiplex PCR (hexaplex \[[@R25]\], GeneScan \[[@R26]\], and MassTag \[[@R27]\]), or microarrays (ViroChip \[[@R28]\] and panmicrobial GreeneChips \[[@R29]\]) may therefore allow us to gain new insights into epidemiology and clinical associations \[[@R30], [@R31]\]. With respect to HRV, recent studies employing sensitive PCR systems for these difficult-to-isolate organisms have shown an increased detection rate, compared with culture methods \[[@R1], [@R32]\]. Applying a multiplex MassTag PCR platform, we recently detected numerous agents of respiratory illness in samples that had been submitted for laboratory diagnosis but that had tested negative during routine diagnostic assessment \[[@R30]\]. HRVs were identified at high frequency in this set of samples. Detailed genetic analysis indicated that a large fraction of these viruses represent a previously uncharacterized genotype of rhinovirus, one that diverges from either HRV-A or HRV-B.

In an attempt to gather additional information on the potential pathogenicity, as well as temporal and geographic distribution, of rhinoviruses, including the recently identified genotype, we evaluated specimens collected, during the 2003--2006 seasons in Bad Kreuznach, Germany, from children hospitalized because of severe LRTI.

Materials and Methods
=====================

***Clinical specimens and sample collection.*** Nasopharyngeal aspirates were obtained from children admitted, because of acute respiratory-tract infection, to the Kreuznacher Diakonie Hospital (Bad Kreuznach, Germany) during the interval of 2003--2006. Individuals ranged in age from 2 weeks to 5 years (mean age, 5 months; median age, 10 months); 46% were male, 54% female. Specimens collected at the time of admission were forwarded undiluted to the Robert Koch Institute (Berlin, Germany) for laboratory evaluation.RNAextraction was performed by use of QIAamp Viral RNA Kits (Qiagen). The 97 samples for which no pathogen had been diagnosed after assessment by realtime reverse-transcription (RT)-PCR assay for influenza virus \[[@R36]\] and respiratory syncytial virus infection were stored at −70°C (2003--2004 season, *n* = 30; 2004--2005 season, *n* = 27; 2005--2006 season, *n* = 40 \[assay details available on request\]).

***Assay procedures.*** The 97 RNA samples representing cases of undiagnosed respiratory diseases were employed as a template for cDNA synthesis by use of Superscript II kits with random hexamer priming (Invitrogen), and they were analyzed by MassTag PCR by using a viral primer panel \[[@R27]\] that targeted influenza virus A and B (FLUAV and FLUBV, respectively), respiratory syncytial virus A and B (RSV-A and RSV-B, respectively), human parainfluenza virus 1, 2, 3, and 4 (HPIV-1, HPIV-2, HPIV-3, and HPIV-4, respectively), human coronavirus 229E and OC-43 (HCoV-229E and HCoV-OC43, respectively), human metapneumovirus, entero- and rhinoviruses, and adenoviruses. The fidelity of the MassTag PCR signal was verified by reamplification of products and by sequence analysis for all positive specimens. In instances in which MassTag PCR indicated the presence of a picornavirus, the VP4/VP2 region was amplified \[[@R37]\]. Amplification products were purified from agarose gels (Qia Gel Extraction Kit; Qiagen), and nucleotidesequencing reactions were performed on both strands by use of the ABI Prism Big Dye cycle sequencing kits and the ABI Prism Genetic Analyzer systems (Applied Biosytems). Identical results were obtained with duplicate aliquots processed at the New York and Berlin laboratories. Sequence analyses, alignments, and phylogenetic reconstructions were performed by use of programs from the Wisconsin GCG Package (Accelrys) and by MEGA3.1 software \[[@R38]\]. Nucleic-acid sequences generated during this work are available at GenBank, under the accession numbers EU081778--EU081816.

Results
=======

***Identification of pathogens.*** We used MassTag PCR to investigate 97 nasopharyngeal aspirates from children hospitalized because of acute respiratory illness for which no pathogen was identified through routine laboratory testing. MassTag PCR identified at least 1 candidate respiratory-viral pathogen in 49 specimens. Although there was variability across the 3 seasons included in this study, 43% of specimens were positive in the 2003--2004 season, 70% of specimens were positive in the 2004--2005 season, and 43% of specimens were positive in the 2005--2006 season. Picornaviruses represented the majority of identified viruses in each season ([table 1](#F2){ref-type="fig"}). For purposes of molecular identification, nucleic-acid sequences were obtained from all specimens that MassTag PCR had identified as being positive for virus. We identified 3 cases of human adenovirus (HAdV) infection---1 HAdV-B and 2 HAdV-C ([table 1](#F2){ref-type="fig"}). In the case of the picornavirus-positive specimens, we identified, by use of molecular typing, 1 human enterovirus 68 (HEV-68), 8 HRV-A, and 3 HRV-B infections; the remaining 30 HRV sequences (HRV X) did not match with known HRV-A, HRV-B, or HEV sequences.

***Clinical associations.*** HRVs were the viruses most frequently detected in our set of samples, representing 75% (41/55) of the identified viruses; coinfection with another virus was observed in only 12% (5/41) of these cases ([table 2](#F3){ref-type="fig"}). The frequency of fever or cough in infections with HRV (82%) was comparable to that in infections with the other viruses (89%); the frequency of rhinitis or pharyngitis with HRV (79%) was comparable to that with other viruses; and the frequency of LRTI symptoms (bronchitis, bronchiolitis, and pneumonia) with HRV (71%) was comparable to that with the other viruses (67%). Whereas pneumonia was more common in infections with HRV A/B (56%) than in infections with HRV X (36%), the frequency of bronchiolitis with HRV A/B (11%) was comparable to that with HRV X (12%), and the frequency of bronchitis with HRV A/B (67%) was comparable to that with HRV X (60%). LRTI was recorded in 72% of HRV X infections; however, some cases were related to milder disease ([table 2](#F3){ref-type="fig"}).

Molecular epidemiology of identified picornaviruses. MassTag PCR targets conserved sequences in the 5′-untranslated region of entero- and rhinoviruses; thus, to facilitate phylogenetic analysis of HEV and HRV, we amplified and sequenced the VP4/VP2 gene region. However, when we used the Basic Local Alignment Search Tool for analysis at the nucleotide level, we did not find, for 30 of the VP4/VP2 sequences, a significant match with HRV-A, HRV-B, or HEV sequences; analysis at the amino-acid level revealed homology to enteroand rhinoviral sequences, with a sequence identity of 60%--65%. High similarity at both the nucleotide- and amino-acid levels was evident when sequences were aligned with an unclassified genetic clade of picornaviruses recently identified in New York State \[[@R30]\]. However, detailed phylogenetic analysis indicated significant sequence diversity among the 30 viruses ([figure 1](#F1){ref-type="fig"}). Temporal analysis over 3 seasons indicated a lower frequency of the novel genotype during the 2003 season (20% \[6/30\]) compared with the 2004 (41% \[11/27\]) and 2005 (33% \[13/40\]) seasons; phylogenetic clustering by season was not obvious. No significant relationship between the HRV genotypes and clinical diagnoses was observed ([figure 1](#F1){ref-type="fig"}).

Discussion
==========

In this study of samples collected, during a 3-year interval, from hospitalized children with severe undiagnosed respiratory infection, MassTag PCR allowed us to detect viral pathogens in 49 (51%) of 97 cases. The pathogens most commonly identified were HRVs. These findings are consistent with other studies, which have indicated that rhinoviruses or picornaviruses account for 20%--80% of acute respiratory infections \[[@R1], [@R32], [@R33], [@R39]\]---exceeding, in some instances, even the frequency of RSV infection in pediatric-patient populations \[[@R34], [@R41]\].

The presence of HRV is not sufficient to prove causation. Asymptomatic HRV infection has been described; however, the extent to which infection without disease represents carriage, incubation, or convalescence is unknown \[[@R35], [@R39], [@R40], [@R42], [@R44]\]. Although we did not have samples to test for the presence of HRV in the lower respiratory tract, the high frequency at which HRV was identified as being the sole virus detected suggests a correlation between the agent and the observed LRTI symptoms. Support for the plausibility of HRV being pathogenic in LRTI comes from the facts that (1) in situ hybridization has demonstrated that HRVs exist in lower airways and (2) HRVs have been shown to trigger inflammatory processes in the infected cells and tissues \[[@R5], [@R45]\].

Among the HRVs identified in the present study were representatives of the novel genetic clade recently discovered in New York State \[[@R30]\]; indeed, these viruses comprised the majority of HRVs detected. HRV-A and HRV-B have been implicated in common colds as well as in severe LRTI. In our patients, viruses of the novel genetic clade were also associated with a wide range of diseases, ranging from rhinitis to bronchitis to severe pneumonia, necessitating supplemental oxygen in ∼50% of cases. A seasonal pattern of HRV infections has been described \[[@R2], [@R3], [@R43]\]; however, data regarding either serotype- or genotype-specific patterns of seasonality or disease symptoms are limited \[[@R49]\]. A temporal trend of sequence diversity or of correlation between genotype (within the novel HRV clade) and clinical diagnosis was not apparent in our data ([figure 1](#F1){ref-type="fig"}).

No detailed information is available yet concerning the history of the novel HRV clade; nonetheless, the sequence diversity observed within it ([figure 1](#F1){ref-type="fig"}) is not consistent with a recent introduction. This clade may account, in part, for earlier reports of nontypeable rhinoviruses \[[@R41], [@R44]\]. Indeed, its discovery may reflect the implementation of new technologies rather than novelty of the agent itself. We anticipate that future work will define more than 1 serogroup. Our findings reinforce other groups\' recent work indicating the significance of HRVs in pediatric LRTI. The presence of novel HRVs in 2 disparate geographic locations, in association with serious respiratory disease in children as well as in adults, mandates further work in epidemiology and pathogenesis.
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